7.46
price up icon1.50%   0.11
after-market Handel nachbörslich: 7.46
loading
Schlusskurs vom Vortag:
$7.35
Offen:
$7.3
24-Stunden-Volumen:
232.56K
Relative Volume:
0.93
Marktkapitalisierung:
$812.91M
Einnahmen:
$106.66M
Nettoeinkommen (Verlust:
$15.16M
KGV:
79.79
EPS:
0.0935
Netto-Cashflow:
$6.37M
1W Leistung:
-1.97%
1M Leistung:
-17.75%
6M Leistung:
-38.35%
1J Leistung:
-38.04%
1-Tages-Spanne:
Value
$6.98
$7.59
1-Wochen-Bereich:
Value
$6.98
$8.00
52-Wochen-Spanne:
Value
$6.11
$19.00

Gyre Therapeutics Inc Stock (GYRE) Company Profile

Name
Firmenname
Gyre Therapeutics Inc
Name
Telefon
(619) 949-3681
Name
Adresse
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Name
Mitarbeiter
574
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
GYRE's Discussions on Twitter

Vergleichen Sie GYRE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GYRE
Gyre Therapeutics Inc
7.46 812.91M 106.66M 15.16M 6.37M 0.0935
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-11 Eingeleitet Noble Capital Markets Outperform
2021-04-29 Fortgesetzt Stephens Overweight
2021-02-10 Eingeleitet Piper Sandler Overweight
2020-05-21 Eingeleitet Raymond James Outperform
2019-01-04 Eingeleitet Oppenheimer Outperform
2018-02-12 Bestätigt B. Riley FBR, Inc. Buy
2018-02-09 Bestätigt Chardan Capital Markets Buy
2017-12-08 Eingeleitet B. Riley FBR, Inc. Buy
2017-06-12 Eingeleitet Chardan Capital Markets Buy
2017-06-06 Eingeleitet Ladenburg Thalmann Buy
2016-06-30 Eingeleitet Rodman & Renshaw Buy
Alle ansehen

Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten

pulisher
Jun 13, 2025

Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials - MSN

Jun 13, 2025
pulisher
Jun 10, 2025

Gyre Therapeutics announces first doing in Phase 1 trial of F230 - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Gyre Therapeutics (GYRE) Begins Phase 1 Trial for Pulmonary Hypertension Drug | GYRE Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - TradingView

Jun 10, 2025
pulisher
Jun 10, 2025

Novel PAH Drug Enters Clinical Trials in $370M China Market, Targeting Rare Disease with High Mortality - Stock Titan

Jun 10, 2025
pulisher
Jun 06, 2025

Gyre Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 06, 2025
pulisher
May 29, 2025

Gyre Therapeutics Closes $23 Million Public Offering - MarketScreener

May 29, 2025
pulisher
May 29, 2025

Gyre Therapeutics Raises $23M in Public Offering for MASH Clinical Trials | GYRE Stock News - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Northern Trust Corp Buys 8,624 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

May 29, 2025
pulisher
May 29, 2025

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Globe and Mail

May 29, 2025
pulisher
May 27, 2025

What's Behind The Big Stock Moves? GYRE, KYTX, TNGX... - Nasdaq

May 27, 2025
pulisher
May 27, 2025

MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday - Benzinga

May 27, 2025
pulisher
May 26, 2025

GNI Group Prices Public Offering at $20 Million to Fund Clinical Trials - marketscreener.com

May 26, 2025
pulisher
May 25, 2025

Gyre Therapeutics slumps 16%, prices $20M stock offering - MSN

May 25, 2025
pulisher
May 25, 2025

Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – What’s Next? - Defense World

May 25, 2025
pulisher
May 23, 2025

Gyre Therapeutics announces new stock offering By Investing.com - Investing.com Nigeria

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics (GYRE) Launches $20 Million Public Offering - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics Announces Stock Offering Agreement - TipRanks

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics announces new stock offering - Investing.com

May 23, 2025
pulisher
May 23, 2025

GYRE Trading Resumes After Temporary Halt | GYRE Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility | GYRE Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics commences underwritten public offering - MSN

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics Prices $20 Million Common Stock Offering - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

GYRE Announces Pricing Below Previous Closing Price | GYRE Stock News - GuruFocus

May 23, 2025
pulisher
May 22, 2025

Gyre Therapeutics Raises $20M in Public Offering to Advance MASH Liver Fibrosis Treatment - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Announces Pricing Of $20 Million Public Offering Of Common Stock At $9.00 Per Share - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Meets Primary Endpoint for Compound to Treat Liver Fibrosis - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone in Phase 3 Trial | GYRE Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics tumbles after stock offering launch - TradingView

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics launches public stock offering By Investing.com - Investing.com Canada

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics (GYRE) Launches Public Offering to Fund Clinical Trial and Growth | GYRE Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Announces Positive Phase 3 Trial Results for Hydronidone in Liver Fibrosis Treatment, Paving Way for NDA Submission in 2025 - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Seeks Fresh Capital: Public Offering to Accelerate Phase 2 MASH Treatment Trial - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Breakthrough in Liver Disease: Gyre's Phase 3 Drug Achieves 53% Fibrosis Regression, First-in-Class Potential - Stock Titan

May 22, 2025
pulisher
May 15, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE) Shares Purchased by Barclays PLC - Defense World

May 15, 2025
pulisher
May 14, 2025

Gyre Therapeutics Reports Q1 2025 Financial Results - MSN

May 14, 2025
pulisher
May 14, 2025

Wells Fargo & Company MN Has $49,000 Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

May 14, 2025
pulisher
May 13, 2025

GYRE Makes Bullish Cross Above Critical Moving Average - Nasdaq

May 13, 2025
pulisher
May 12, 2025

1 Stock to Buy Hand Over Fist as ‘Risk On’ Sentiment Gains Momentum - The Globe and Mail

May 12, 2025
pulisher
May 11, 2025

Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – Here’s Why - Defense World

May 11, 2025
pulisher
May 09, 2025

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 09, 2025
pulisher
May 09, 2025

Gyre Therapeutics Reports Q1 2025 Revenue of $22.1 Million and Progress in Clinical Development and Commercialization Efforts - Nasdaq

May 09, 2025
pulisher
May 09, 2025

Earnings Flash (GYRE) Gyre Therapeutics Reports Q1 Revenue $22.1M, vs. FactSet Est of $28.4M - marketscreener.com

May 09, 2025
pulisher
May 07, 2025

Taking A Look At Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE - simplywall.st

May 07, 2025
pulisher
May 07, 2025

A Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To Equity - Yahoo Finance

May 07, 2025
pulisher
May 05, 2025

Gyre Therapeutics Inc expected to post earnings of 3 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 02, 2025

GYREGyre Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

May 02, 2025

Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Gyre Therapeutics Inc-Aktie (GYRE) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Ma Songjiang
President
May 28 '25
Sale
10.07
558
5,619
2,806,084
Ma Songjiang
President
May 22 '25
Sale
10.97
2,000
21,940
2,808,824
Ma Songjiang
President
May 23 '25
Sale
10.24
182
1,864
2,808,642
Ma Songjiang
President
May 20 '25
Sale
11.25
2,000
22,500
2,812,824
Ma Songjiang
President
May 21 '25
Sale
10.83
2,000
21,660
2,810,824
Ma Songjiang
President
May 16 '25
Sale
11.31
2,000
22,620
2,816,824
Ma Songjiang
President
May 19 '25
Sale
11.11
2,000
22,220
2,814,824
Ma Songjiang
President
May 15 '25
Sale
10.68
2,000
21,360
2,818,824
Ma Songjiang
President
May 14 '25
Sale
11.30
20
226
2,820,824
Ye Weiguo
Chief Operating Officer
Apr 01 '25
Option Exercise
0.75
50,000
37,500
700,000
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):